New hope for lymphoma patients when CAR-T fails: tailored drug cocktail shows promise
NCT ID NCT07602322
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a personalized treatment approach for people with large B-cell lymphoma whose cancer did not respond to CAR-T cell therapy. Researchers will analyze the tumor's surrounding environment to classify it into one of four subtypes, then give patients a drug combination tailored to that subtype. The goal is to see if this customized strategy helps patients live longer without their cancer progressing compared to a standard single drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Glofitamab combined with other drugs (BCL-2 inhibitor, PD-1 inhibitor, lenalidomide, radiotherapy, BTK inhibitor, or HDAC inhibitor) based on tumor subtype
- What this could lead to
- If successful, this could offer a more effective treatment option for patients with large B-cell lymphoma who have not responded to CAR-T therapy, potentially extending the time they live without their disease worsening.
- What could go wrong
- This is a small, early-phase trial with only 60 participants, so results may not apply to all patients. The personalized approach is new and may not work better than standard therapy, and combination drugs can have significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai,
Shanghai, Shanghai Municipality, 200020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a single shot build a cancer army inside the body?
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Engineered immune cells get a boost: new combo therapy targets Hard-to-Treat blood cancers
- New combo aims to boost lymphoma control in older patients
- New hope for lymphoma patients when CAR-T fails